Kush Arvind 4

What Happened Kush Arvind, a director of Inhibikase Therapeutics, was granted 155,000 derivative securities (stock options/awarded shares) on June 26, 2026. The reported acquisition price is $0.00, indicating these were an awarded grant rather than an open‑market purchase or sale. No immediate cash changed hands and no exercise or sale of existing holdings was reported.

Key Details

• Transaction date: 2026-06-26; Filing date: 2026-06-30 (filed within the standard 2-business-day window).
• Reported amount: 155,000 derivative shares/options; reported acquisition price $0.00.
• Shares/ownership after transaction: not specified in the provided filing excerpt.
• Footnote: the options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to continued service.
• Transaction type code: A (award/grant); treated as compensation, not a market purchase (no 10b5-1 or tax‑withholding noted in the excerpt).

Context This was a compensation grant to a director rather than a buy or sell in the open market. Such awards are common for board service and don’t by themselves signal buying or selling intent. Because these are derivative awards that vest over time, the director does not receive immediately tradable shares until vesting (and any subsequent exercise if they are options).